Lung Cancer News

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer (November 29, 2019)

The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many... Continue Reading

Alunbrig Continues to Demonstrate Superiority in the First – Line After Two Years of Follow-Up for ALK + NSCLC (November 27, 2019)

Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received... Continue Reading

E-Cigarette Smoke Causes Lung Cancer in Mice (October 8, 2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC (October 4, 2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC (September 27, 2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the... Continue Reading

FDA Approves Keytruda for Small Cell Lung Cancer (June 18, 2019)

The  Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of... Continue Reading

Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC (November 8, 2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori... Continue Reading

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC (November 5, 2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed... Continue Reading

November Is National Lung Cancer Awareness Month (October 23, 2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the... Continue Reading

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone (October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading

Latest Lung Cancer News By Stage


General Lung Cancer

Sorry, there are no articles available for this cancer stage.

More General Lung Cancer